Catalyst Tracker
01/08/2025 09:32 PM ET
Calidi CLDI -30% AH Offering; Silo Pharma SILO +55% Patent
Due to the US marketing being closed in observance for a day of mourning for former President Jimmy Carter, we will not be sending out our Pre-Market Movers or Daily Updates newsletters on Thursday, January 9, 2025. Calidi Biotherapeutics, Inc. (NYSE: [...]
Read More01/07/2025 09:24 PM ET
Hoth HOTH +178% Phase 2a Data; Sana SANA +234% AH Data
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shared interim safety and efficacy results from its Phase 2a CLEER-001 clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients.100% of patients in cohort [...]
Read More01/06/2025 08:49 PM ET
Predictive POAI +58% Acquired by Renovaro RENB; SciSparc +103% European Patent
Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced it has entered into a binding LOI to acquire Predictive Oncology (NASDAQ: POAI) in an all-stock transaction. Renovaro will acquire 100% of Predictive Oncology [...]
Read More01/03/2025 05:10 PM ET
Check-Cap CHEK +53% Patent; Bionano BNGO +24% Offering
Bionano Genomics, Inc. (NASDAQ: BNGO) entered into an approximately $10 million registered direct offering agreement with institutional investors for the sale of 39,682,540 shares of common stock and warrants to purchase an equal number of shares at a combined price [...]
Read More01/02/2025 09:10 PM ET
Neumora NMRA -81% Phase 3 Failure; Curis CRIS +39% Patent
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced that the Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not achieve statistically significant improvements in the primary MADRS score at Week 6 or the key secondary SHAPS score. The KOASTAL-2, [...]
Read More12/23/2024 08:43 PM ET
Traws TRAW +150% Preclinical Data; Rapt RAPT +111% Deal
In observance of Christmas and the New Year we will not be sending out the Pre-Market Newsletter from December 24 - January 1, 2024. We will still be sending our Weekly Watchlist and Community Newsletters on their normal schedule. Traws Pharma, [...]
Read More12/20/2024 04:57 PM ET
Aadi AADI +46% Asset Sale; Aptose APTO +64% NASDAQ Compliance
In observance of Christmas and the New Year, we will not be sending out the Pre-Market Newsletter from December 24 - January 1, 2024. We will still be sending our Weekly Watchlist and Community Newsletters on their normal schedule. Lexicon Pharmaceuticals, [...]
Read More12/19/2024 09:10 PM ET
BioPath BPTH +123% Prioritization; Aptose APTO +135% AH Nasdaq Extension
In observance of Christmas and the New Year, we will not be sending out the Pre-Market Newsletter from December 24 - January 1, 2024. We will still be sending our Weekly Watchlist and Community Newsletters on their normal schedule. Bio-Path Holdings [...]
Read More12/18/2024 08:13 PM ET
TC BioPharm TCBP +39% Special Dividend; Cognition Therapeutics CGTX +28% Phase 2 Data
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced topline results from its Phase 2 SHIMMER study, where CT1812 met safety and tolerability endpoints, significantly slowing neuropsychiatric decline by 82% in dementia with Lewy bodies patients and reducing attention fluctuations by 91% compared [...]
Read More12/17/2024 09:04 PM ET
Petros PTPI +87% Strategic Shift; Portage PRTG +178% Letter of Intention
Petros Pharmaceuticals (NASDAQ: PTPI) announced a strategic shift to focus on its proprietary technology platform, designed to facilitate Rx-to-OTC switches across various therapies. This Software as a Service and Software as a Medical Device platform aims to capitalize on the [...]
Read More12/16/2024 09:20 PM ET
Daily Updates 12/16/24: Tonix TNXP +120% NDA Submitted; Larimar LRMR -22% OLE Data
Tonix Pharmaceuticals (NASDAQ: TNXP) submitted an NDA to the FDA for TNX-102 SL, a non-opioid analgesic for fibromyalgia, supported by two positive Phase 3 studies. Shares closed up 120% at $0.53. Larimar Therapeutics (NASDAQ: LRMR) reported data from its open-label extension [...]
Read More12/13/2024 05:10 PM ET
Curative CUBT +52% Strategic Advisor; Repare Therapeutics RPTX -55% Phase 1 Data
Curative Biotechnology Inc. (OTC: CUBT) announced the engagement of Golden Eagle Capital Advisors, Inc (GECA), a financial advisory group based in Dubai as the exclusive agent and strategic advisor to the company. Shares closed up 52% at $0.01. Repare Therapeutics Inc. [...]
Read More
